Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective

被引：23

作者：

Todesco, Eve ^{[1
,2
]}

Mazzola, Alessandra ^{[3
]}

Akhavan, Sepideh ^{[2
,4
]}

Abravanel, Florence ^{[5
,6
]}

Poynard, Thierry ^{[7
,8
,9
]}

Roque-Afonso, Anne-Marie ^{[10
]}

Peytavin, Gilles ^{[11
,12
]}

Marcelin, Anne-Genevieve ^{[1
,2
]}

Calmus, Yvon ^{[3
]}

Lecuyer, Lucien ^{[13
]}

Guillemain, Romain ^{[14
]}

Conti, Filomena ^{[3
]}

机构：

[1] UPMC Univ Paris 06, Sorbonne Univ, INSERM, IPLESP,UMRS 1136, Paris, France

[2] Hop La Pitie Salpetriere, AP HP, Dept Virol, Paris, France

[3] UPMC Paris VI, Hop Pitie Salpetriere, AP HP, Unite Med Transplantat Hepat,Hepatogastroenterol, Blvd Hop, Paris, France

[4] UPMC Univ Paris 06, Sorbonne Univ, CIMI Paris UMRS CR7, PVI Team,Inserm,U1135, Paris, France

[5] CHU Toulouse, Hop Purpan, Lab Virol, Natl Reference Ctr Hepatitis E, Toulouse, France

[6] INSERM, Ctr Physiopathol Toulouse Purpan, U1043, Toulouse, France

[7] Grp Hosp Pitie Salpetriere, AP HP, Paris, France

[8] UPMC Univ Paris 06, Sorbonne Univ, UMR S 938, Paris, France

[9] INSERM, Inst Cardiometab & Nutr ICAN, Paris, France

[10] Univ Paris Sud, Hop Paul Brousse, AP HP, INSERM,Virol,U1193, Villejuif, France

[11] Bichat Claude Bernard Hosp, AP HP, Pharmacotoxicol Dept, Paris, France

[12] Univ Paris Diderot, Sorbonne Paris Cite, IAME, INSERM,UMR 1137, Paris, France

[13] Univ Paris 05, Hop Europeen Georges Pompidou, AP HP, Serv Chirurg Cardiovasc, Paris, France

[14] Hop Europeen Georges Pompidou, AP HP, Pole Cardiovasc Nephrol Hypertens Diabet, Unite Fonct Transplantat Thorac, Paris, France

来源：

ANTIVIRAL THERAPY | 2018年 / 23卷 / 05期

关键词：

E VIRAL-INFECTION; REPLICATION;

D O I：

10.3851/IMP3227

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Hepatitis E virus (HEV) can induce chronic infections in the case of immunosuppression, which are sometimes not cured with ribavirin. Furthermore, sofosbuvir is a highly potent inhibitor of HCV polymerase and was shown to inhibit HEV genotype-3 replication in vitro. We report here the outcome of sofosbuvir/ribavirin therapy on a chronic HEV infection in a heart transplant recipient non-responder to ribavirin. After 24 weeks, the regimen failed to cure the persistent HEV infection, highlighting the need of therapeutic options for HEV-infected immunosuppressed patients.

引用

页码：463 / 465

页数：3

共 50 条

[31] Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant
Mohamed Shoreibah
Jordan Orr
DeAnn Jones
Jie Zhang
Krishna Venkata
Omar Massoud
Hepatology International, 2017, 11 : 434 - 439
[32] Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant
Shoreibah, Mohamed
Orr, Jordan
Jones, DeAnn
Zhang, Jie
Venkata, Krishna
Massoud, Omar
HEPATOLOGY INTERNATIONAL, 2017, 11 (05) : 434 - 439
[33] HEPATITIS E VIRUS INFECTION IN HEART TRANSPLANT RECIPIENTS: HEV SEROPREVALENCE, RISK FOR CHRONIC COURSES AND EFFICACY OF RIBAVIRIN TREATMENT
Pischke, Sven
Stiefel, Penelope
Bremer, Birgit
Suneetha, Pothakamuri V.
Franz, Beate
Heim, Albert
Ganzenmueller, Tina
Schlue, Jerome
Horn-Wichmann, Ruediger
Raupach, Regina
Scheibner, Yves
Haverich, Axel
Manns, Michael P.
Bara, Christoph L.
Wedemeyer, Heiner
HEPATOLOGY, 2011, 54 : 617A - 617A
[34] Chronic hepatitis E infection with an emerging virus strain in a heart transplant recipient successfully treated with ribavirin: A case report
Waldenström J.
Castedal M.
Konar J.
Karason K.
Lagging M.
Norder H.
Journal of Medical Case Reports, 9 (1)
[35] Ledipasvir/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection
Gallacher, Jennifer
Taha, Yusri
Filipe, Ana da Silva
Ijaz, Samreen
McPherson, Stuart
IDCASES, 2023, 32
[36] Safety and Efficacy of Sofosbuvir Plus Ribavirin and Sofosbuvir Plus Daclatasvir With or Without Ribavirin Combinations in Children and Adolescents With Chronic Hepatitis C
Hassan, Adil
Bughio, Ubedullah
Bhatti, Rehmatullah
Ali, Mashooque
Jamali, Laraib
Sadik, Muhammad
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S592 - S592
[37] Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus
Morales, Amilcar L.
Liriano-Ward, Luz
Tierney, Amber
Sang, Michelle
Lalos, Alexander
Hassan, Mohamed
Nair, Vinay
Schiano, Thomas
Satoskar, Rohit
Smith, Coleman
CLINICAL TRANSPLANTATION, 2017, 31 (05)
[38] Sofosbuvir/Velpatasvir ± Ribavirin for Retreatment of Patients with Chronic Hepatitis C Virus (HCV) Infection Failing to a Previous Daa Combination Regimen
Brancaccio, Giuseppina
Martini, Silvia
Ciancio, Alessia
Volpes, Riccardo
Di Stefano, Marco
Masarone, Mario
Messina, Vincenzo
Montineri, Arturo
Biolato, Marco
Brillanti, Stefano
Claar, Ernesto
Dell'Isola, Chiara
Lionetti, Raffaella
Montalbano, Marzia
Picciotto, Antonin
Sollima, Salvatore
Taibi, Chiara
Teti, Elisabetta
Ucciferri, Claudio
Cirillo, Paolo
Gaeta, Giovanni B.
HEPATOLOGY, 2018, 68 : 416A - 417A
[39] Sofosbuvir Add-on to Ribavirin Treatment for Chronic Hepatitis E Virus Infection in Solid Organ Transplant Recipients Does Not Result in Sustained Virological Response
van Wezel, E. M.
de Bruijne, J.
Damman, K.
Bijmolen, M.
van den Berg, A. P.
Verschuuren, E. A. M.
Ruigrok, G. A.
Riezebos-Brilman, A.
Knoester, M.
OPEN FORUM INFECTIOUS DISEASES, 2019, 6 (08):
[40] Outcome of Treatment With Pegylated Interferon and Ribavirin in Heart Transplant Recipients With Chronic Hepatitis C
Durante-Mangoni, E.
Ragone, E.
Pinto, D.
Iossa, D.
Covino, F. E.
Maiello, C.
Utili, R.
TRANSPLANTATION PROCEEDINGS, 2011, 43 (01) : 299 - 303

← 1 2 3 4 5 →